Our dedication to discovery remains unwavering after more than 30 years of investigating potential life-changing treatments for patients with neurological, neuroendocrine, and neuropsychiatric disorders.

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. [1] It is headquartered in San Diego, California, and led by CEO Kevin Gorman. [3] Neurocrine develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine was founded in 1992 by Wylie Vale, Ph.D., of the Salk Institute for Biological Studies, where he contributed to Nobel Prize–winning work in endocrinology, and award-winning Stanford University neurologist Lawrence Steinman, Ph.D.

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders.

Neurocrine Biosciences has global rights unless otherwise noted. * Mitsubishi Tanabe Pharma Corporation has commercialization rights in Japan and other select Asian markets. ± Takeda Pharmaceutical Company Limited has retained rights in Japan.

Dec 16, 2024 · Neurocrine Biosciences stock jumped Monday after the company won FDA approval for the first new treatment for an adrenal disease in decade

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its two New Drug Applications (NDA) with Priority Review designations for ...

You Deserve Brave Science | Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs.

SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive top-line data from the Phase 3 CAHtalyst™ Adult Study evaluating the efficacy, safety, and tolerability of crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD).

On Friday, the FDA approved Neurocrine Biosciences, Inc.(NASDAQ:NBIX) Crenessity (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control ...